Palvella Therapeutics Receives FDA Fast Track Status for Angiokeratoma Treatment
The FDA has bestowed Fast Track Designation upon Palvella Therapeutics' (PVLA) treatment approach using rapamycin to address angiokeratomas, marking a significant milestone in the drug's development pathway. This regulatory recognition streamlines the review process and opens possibilities for accelerated approval routes and expedited evaluation if specific clinical milestones are achieved.
**Background on the Development Program**
Following its September 2025 announcement, Palvella Therapeutics expanded QTORIN ra
The FDA has bestowed Fast Track Designation upon Palvella Therapeutics' (PVLA) treatment approach using rapamycin to address angiokeratomas, marking a significant milestone in the drug's development pathway. This regulatory recognition streamlines the review process and opens possibilities for accelerated approval routes and expedited evaluation if specific clinical milestones are achieved.
**Background on the Development Program**
Following its September 2025 announcement, Palvella Therapeutics expanded QTORIN ra